SUDA Pharmaceuticals Ltd. announced that the Ministry of Health, Chile, has approved the registration of the Company's lead product ZolpiMist (zolpidem tartrate) by Teva Pharmaceuticals for the treatment of short-term insomnia in adults. SUDA's partner, Teva Pharmaceuticals, submitted a Marketing Authorisation Application (MAA) with the new supplemental API supplier and the Australian final product manufacturer to the Chilean authority for ZolpiMist in May 2021. Approval was granted significantly sooner than the expected date of April 2022. The improved supply chain allows SUDA to supply the product at a more competitive supply price. The benefits of the Chile approval are: ZolpiMist can be commercialised and supplied within Chile; It demonstrates compliance with international Good Manufacturing Practice and an ability to obtain regulatory approvals with partners.